Predicting Responses to Pregabalin for Painful Diabetic Peripheral Neuropathy Based on Trajectory-Focused Patient Profiles Derived from the First 4  Weeks of Treatment

ConclusionBy correctly predicting 12- to 13-week responder outcomes with 90% accuracy based on responses from the first month of treatment, we demonstrated the value of trajectory measures in predicting pDPN patient response to pregabalin.Trial Registrationwww.clinicaltrials.gov identifiers, NCT00156078/NCT00159679/NCT00143156/NCT00553475.FundingPfizer.Plain Language SummaryPlain language summary available for this article.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research